Somatostatin Receptor Subtypes, Octreotide Scintigraphy, and Clinical Response to Octreotide Treatment in Patients with Neuroendocrine Tumors

1998 ◽  
Vol 22 (7) ◽  
pp. 679-683 ◽  
Author(s):  
Lars Kölby ◽  
Bo Wängberg ◽  
Håkan Ahlman ◽  
Lars-Erik Tisell ◽  
Martha Fjälling ◽  
...  
Keyword(s):  
Clinical Response ◽  
Neuroendocrine Tumors ◽  
Somatostatin Receptor ◽  
Receptor Subtypes ◽  
Somatostatin Receptor Subtypes ◽  
Octreotide Scintigraphy ◽  
Octreotide Treatment

Prognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors

Pancreas ◽  
2016 ◽  
Vol 45 (2) ◽  
pp. 187-192 ◽  
Author(s):  
Ki Byung Song ◽  
Song Cheol Kim ◽  
Ji Hun Kim ◽  
Dong-Wan Seo ◽  
Seung-Mo Hong ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Prognostic Value ◽  
Somatostatin Receptor ◽  
Receptor Subtypes ◽  
Pancreatic Neuroendocrine Tumors ◽  
Somatostatin Receptor Subtypes

Monoclonal Antibodies against the Human Somatostatin Receptor Subtypes 1–5: Development and Immunohistochemical Application in Neuroendocrine Tumors

2011 ◽  
Vol 95 (3) ◽  
pp. 232-247 ◽  
Author(s):  
Herbert A. Schmid ◽  
Chiara Lambertini ◽  
Harmke H. van Vugt ◽  
Patrizia Barzaghi-Rinaudo ◽  
Judith Schäfer ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Neuroendocrine Tumors ◽  
Somatostatin Receptor ◽  
Receptor Subtypes ◽  
Somatostatin Receptor Subtypes

scholarly journals Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors

2012 ◽  
Vol 19 (5) ◽  
pp. 615-623 ◽  
Author(s):  
Jennifer A Chan ◽  
David P Ryan ◽  
Andrew X Zhu ◽  
Thomas A Abrams ◽  
Brian M Wolpin ◽  
...  
Keyword(s):  
Phase I ◽  
Neuroendocrine Tumors ◽  
Phase I Study ◽  
Tumor Regression ◽  
Somatostatin Receptor ◽  
Preliminary Evidence ◽  
Response To Therapy ◽  
Receptor Subtypes ◽  
Somatostatin Receptor Subtypes ◽  
Grade 3

Octreotide and everolimus have demonstrated efficacy in neuroendocrine tumors. Pasireotide is a somatostatin analog with binding affinity to a broader range of somatostatin receptor subtypes than octreotide. We performed a phase I study to evaluate the safety and feasibility of combining pasireotide with everolimus in patients with advanced neuroendocrine tumors. Cohorts of patients with advanced neuroendocrine tumors were treated with escalating doses of pasireotide (600–1200 μg s.c. b.i.d., followed by pasireotide LAR 40–60 mg i.m. monthly) and everolimus (5–10 mg daily). Twenty-one patients were treated. Dose-limiting toxicities consisting of grade 3 rash and grade 3 diarrhea were observed. Twelve patients were safely treated at the maximum protocol-defined dose level of pasireotide LAR 60 mg i.m. monthly and everolimus 10 mg daily. Hyperglycemia was common; other observed toxicities were consistent with the known toxicities of either agent alone. Partial tumor response was observed in one patient; 17 (81%) patients experienced at least some tumor regression as their best response to therapy. In conclusion, pasireotide LAR 60 mg i.m. monthly in combination with everolimus 10 mg daily is feasible and associated with preliminary evidence of antitumor activity in patients with advanced neuroendocrine tumors. Further studies evaluating this combination are warranted.

Sign in / Sign up

Export Citation Format

Share Document